Immune memory in nonclinical models after treatment with NKTR-214, an engineered cytokine biased towards expansion of CD8+ T cells in tumor.
Deborah H. Charych(Lawrence Berkeley National Laboratory), Jonathan Zalevsky(Nektar Therapeutics (United States)), Vidula Dixit(Nektar Therapeutics (United States)), Murali K. Addepalli(Nektar Therapeutics (United States)), Janet Cetz(Nektar Therapeutics (United States)), Stephen K. Doberstein(Xencor (United States)), Rhoneil Pena(Nektar Therapeutics (United States)), Werner Rubas(University of California, San Francisco), John L. Langowski(Novartis (Switzerland)), Ute Hoch(University of Arizona)
Cited by 1
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403